Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’ Simcere To Sell Its 35% Stake In Shanghai Celgen

This article was originally published in PharmAsia News

Executive Summary

China’sSimcere Pharmaceutical Group plans to sell its 35% stake in Shanghai Celgen Bio-Pharmaceutical Co. Ltd. for $48 million, exiting a deal signed in 2009.

You may also be interested in...



China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma

BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel